Erick Calmet del Castillo, MD
Family Medicine · Hannibal, MONPI 1447401716
Payments from drug & device makers
Across 237 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$796
- Novo Nordisk$474
- Pfizer$361
- Amgen$257
- GSK$251
- AstraZeneca$223
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,713100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $796 |
| Novo Nordisk | 34 | $474 |
| Pfizer | 32 | $361 |
| Amgen | 13 | $257 |
| GSK | 17 | $251 |
| AstraZeneca | 15 | $223 |
| Lilly USA, LLC | 10 | $167 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $148 |
| Mylan Specialty L.p. | 1 | $125 |
| Verona Pharma, Inc. | 4 | $76 |
| Boehringer Ingelheim | 4 | $60 |
| Teva Pharmaceuticals USA, Inc. | 4 | $57 |
| Daiichi Sankyo Inc. | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Astellas Pharma US Inc | 2 | $45 |
| Acadia Pharmaceuticals Inc | 2 | $43 |
| Lundbeck LLC | 2 | $38 |
| Sunovion Pharmaceuticals Inc. | 3 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Nestle Healthcare Nutrition Inc. | 2 | $30 |
| Johnson & Johnson | 2 | $29 |
| Merck | 2 | $28 |
| Sanofi Pasteur Inc. | 2 | $27 |
| Bayer | 1 | $25 |
| Abbott | 1 | $24 |
| Globus Medical | 1 | $24 |
| Alkermes, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Resmed Corp | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$125
How this compares
$3,713 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $82,886 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $68,124 |
| TrulicityDulaglutide | 60 | $57,852 |
| EliquisApixaban | 64 | $47,090 |
| Tresiba Flextouch U-100Insulin Degludec | 56 | $30,304 |
| JardianceEmpagliflozin | 18 | $24,038 |
| JanuviaSitagliptin Phosphate | 30 | $21,001 |
| MounjaroTirzepatide | 15 | $19,901 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 32 | $17,794 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $17,152 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $16,108 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 11 | $15,088 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,793 |
| FarxigaDapagliflozin Propanediol | 13 | $9,112 |
| MyrbetriqMirabegron | 12 | $7,912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $251 | $101,384159 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $474 | $97,97467 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $167 | $77,75375 claims |
| PfizerEliquis | $361 | $47,09064 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $60 | $41,83250 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $223 | $22,90535 claims |
| MerckJanuvia | $28 | $21,00130 claims |
| Astellas Pharma US IncMyrbetriq | $45 | $7,91212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Hannibal
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.